Mirati Therapeutics (MRTX) PT Lowered to $209 at JPMorgan, Following Earnings

May 7, 2021 12:27 PM EDT
Get Alerts MRTX Hot Sheet
Price: $165.33 -0.74%

Rating Summary:
    14 Buy, 7 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 8 | New: 64
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

JPMorgan analyst Anupam Rama lowered the price target on Mirati Therapeutics (NASDAQ: MRTX) to $209.00 (from $225.00) while maintaining a Overweight rating.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change

Related Entities

JPMorgan, Earnings